The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (361.05) USD. With the latest stock price at 24.59 USD, the upside of Nektar Therapeutics based on DCF is -1568.3%.
Based on the latest price of 24.59 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 1568.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 8.5% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (1,687.95) - (206.70) | (361.05) |
| Upside | -6964.4% - -940.6% | -1568.3% |